Obesity Surgery

, Volume 22, Issue 5, pp 827–831

Bariatric Surgery Evolution from the Malabsorptive to the Hormonal Era

Review

Abstract

While bariatric procedures continued to evolve and develop since the 1950s, their classification has not matched this evolution. The procedures are commonly classified into restrictive, malabsorptive, or combined. In this day and age, we recognize different mechanisms of action of the bariatric procedures. This article aims to review and update the old classifications based on our current understanding of the hormonal aspects of the various bariatric procedures and the role of gut hormones in weight loss and treatment of the associated metabolic comorbidities. The article suggests the need for a new classification of the bariatric procedures, based on the mechanism of action, involving the hormonal aspects of the procedure.

Keywords

Gut hormones Ghrelin GLP-1 Peptide YY Gastric bypass Sleeve gastrectomy Gastric band 

References

  1. 1.
    Kremen A, Linner J, Nelson C. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg. 1954;140:439–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Griffen Jr W, Bivins B, Bell R. The decline and fall of jejunoileal bypass. Surg Gynecol Obstet. 1983;157:301–8.PubMedGoogle Scholar
  3. 3.
    Payne J, DeWind L. Surgical treatment of obesity. Am J Surg. 1969;118:141–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Rucker R, Chan E, Horstmann J, et al. Searching for the best weight reduction operation. Surgery. 1984;96:624–31.PubMedGoogle Scholar
  5. 5.
    Payne J, Dewind L, Commons R. Metabolic observations in patients with jejunocolic shunts. Am J Surg. 1963;106:273–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Scopinaro N, Gianetta E, Adami G, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119:261–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Marceau P, Biron S, Bourque R, et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg. 1993;3:29–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Kuzmak L, Yap I, McGuire L, et al. Surgery for morbid obesity using an inflatable gastric band. AORN J. 1990;51:1307–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Yang J, Zhao T, Goldstein J, et al. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A. 2008;105:10750–5.PubMedCrossRefGoogle Scholar
  11. 11.
    De Vriese C, Gregoire F, Lema-Kisoka R, et al. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology. 2004;145:4997–5005.PubMedCrossRefGoogle Scholar
  12. 12.
    Cummings D, Purnell J, Frayo R, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Drazen D, Vahl T, D’Alessio D, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology. 2006;147:23–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1:e62.PubMedCrossRefGoogle Scholar
  15. 15.
    Wren A, Seal L, Cohen M, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.PubMedCrossRefGoogle Scholar
  16. 16.
    Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Cummings D, Weigle D, Frayo R, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Halem H, Taylor J, Dong J, et al. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol. 2004;151:S71–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Kobelt P, Helmling S, Stengel A, et al. Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut. 2006;55:788–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Zorrilla E, Iwasaki S, Moss J, et al. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006;103:13226–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Cytos Biotechnology. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. Cytos Biotechnology. Press release November 7, 2006. Retrieved 2 June 2009.Google Scholar
  22. 22.
    Tan T, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader–Willi syndrome. J Clin Endocrinol Metab. 2004;89:4162–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Adrian T, Bloom S, Bryant M, et al. Distribution and release of human pancreatic polypeptide. Gut. 1976;17:940–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Lieverse R, Masclee A, Jansen J, et al. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion andmodified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord. 1994;18:123–7.PubMedGoogle Scholar
  25. 25.
    Silvestre R, Rodriguez-Gallardo J, Jodka C, et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab. 2001;280:E443–9.PubMedGoogle Scholar
  26. 26.
    Rushing P, Hagan M, Seeley R, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Westermark P, Engstrom U, Johnson K, et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A. 1990;87:5036–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Paik K, Jin D, Lee K, et al. Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader–Willi syndrome. J Korean Med Sci. 2007;22:436–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Batterham R, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006;4:223–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Beckh K, Mönnikes H, Loos S, et al. Low hepatic clearance of peptide YY in the perfused rat liver. Regul Pept. 1992;37:205–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Adrian T, Ferri G, Bacarese-Hamilton A, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070–7.PubMedGoogle Scholar
  32. 32.
    MDRNA. (2008). MDRNA announces phase 2 trial of PYY(3–36) does not meet weight loss endpoint. MDRNA. Press release 31 July 2008.Google Scholar
  33. 33.
    Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides. 2004;38:267–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Bataille D, Gespach C, Tatemoto K, et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides. 1981;2 Suppl 2:41–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Baggio L, Huang Q, Brown T, et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127:546–58.PubMedCrossRefGoogle Scholar
  36. 36.
    Orskov C, Wettergren A, Holst J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31:665–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Mentlein R, Gallwitz B, Schmidt W. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–35.PubMedCrossRefGoogle Scholar
  38. 38.
    Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.PubMedCrossRefGoogle Scholar
  39. 39.
    Pournaras D, Osborne A, Hawkins S, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg. 2010;20:56–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Kotidis EV, Koliakos G, Papavramidis T, et al. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg. 2006;16:554–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Beckman L, Beckman T, Earthman C. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Bohdjalian A, Langer F, Shakeri-Leidenmühler. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20:535–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Tzovaras G, Papamargaritis D, Sioka E, et al. Symptoms suggestive of dumping syndrome after provocation in patients after laparoscopic sleeve gastrectomy. Obes Surg. 2011;22(1):23–8.CrossRefGoogle Scholar
  44. 44.
    Lee WJ, Chen CY, Chong K, et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011;7(6):683–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Bariatric and Advanced Laparoscopic SurgeryPreston Memorial HospitalKingwoodUSA

Personalised recommendations